Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to promote absorption of the bisphosphonate at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising an HDAC inhibitor in combination with an enhancer to promote absorption of the HDAC inhibitor at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.

Abstract: The present invention provides a feedstock for intensive feeding of replacement dairy heifers to promote rapid growth, and facilitate early breeding and first calving at an age of about 20-24 months. The calved heifers subsequently yield increased first lactation milk production and lifetime milk. An essential ingredient of the invention feedstock is conjugated linoleic acid derivative having remen-bypass properties. The quantity of conjugated linoleic acid derivative is effective for prevention of mammary gland tissue damage by minimizing mammary fat content. A preferred feedstock includes a content of slow-release degradable nitrogen source for efficient rumen fermentation, and a content of rumen-bypass protein.